Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial

BACKGROUND: Most older patients with acute myeloid leukemia (AML) who attain morphologic remission with intensive chemotherapy (IC) will eventually relapse and post-relapse prognosis is dismal. In the pivotal QUAZAR AML-001 trial, oral azacitidine maintenance therapy significantly prolonged overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravandi, Farhad, Roboz, Gail J., Wei, Andrew H., Döhner, Hartmut, Pocock, Christopher, Selleslag, Dominik, Montesinos, Pau, Sayar, Hamid, Musso, Maurizio, Figuera-Alvarez, Angela, Safah, Hana, Tse, William, Sohn, Sang Kyun, Hiwase, Devendra, Chevassut, Timothy, Pierdomenico, Francesca, La Torre, Ignazia, Skikne, Barry, Bailey, Rochelle, Zhong, Jianhua, Beach, C. L., Dombret, Herve
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401338/
https://www.ncbi.nlm.nih.gov/pubmed/34454540
http://dx.doi.org/10.1186/s13045-021-01142-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401338/
https://www.ncbi.nlm.nih.gov/pubmed/34454540
http://dx.doi.org/10.1186/s13045-021-01142-x

Ejemplares similares